Sai Life Sciences Ltd

Sai Life Sciences has allotted 129,007 equity shares under ESOP on 22 February 2026. With this allotment, the paid up equity share capital has increased to 21,17,58,134 equity shares of Re 1 each. Powered by Capital Market - Live

On a consolidated basis, the company reported revenue from operations of Rs 556 crore in Q3 FY26, up 27% YoY from Rs 440 crore in Q3 FY25. The company said revenue growth during the quarter was driven by strong momentum in both contract research organisation and contract development and manufacturing organisation segments. Profit after tax stood at Rs 100 crore in Q3 FY26, compared with Rs 54 crore a year ago, translating into an 86% YoY increase. PAT margin improved to 18% from 12% in the corresponding quarter last year. Profit before tax surged 87% YoY to Rs 134 crore in Q3 FY26 from Rs 72 crore in the year-ago quarter. EBITDA increased 54% YoY to Rs 191 crore from Rs 124 crore in Q3 FY25, while EBITDA margin expanded to 34% from 28%. The growth was supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives. Sai Life Sciences said it has invested Rs 405 crore in capital expenditure so far, against a planned capex outlay of Rs 700 crore for FY26, in line with its long-term strategy to strengthen capabilities and expand capacity. During the quarter, it successfully completed eight customer audits across its manufacturing and R&D units, with zero data integrity deviations and no critical observations reported. Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said: Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders. Hyderabad-based Sai Life Sciences is one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Powered by Capital Market - Live

Net profit of Sai Life Sciences rose 86.41% to Rs 100.38 crore in the quarter ended December 2025 as against Rs 53.85 crore during the previous quarter ended December 2024. Sales rose 26.53% to Rs 556.46 crore in the quarter ended December 2025 as against Rs 439.78 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales556.46439.78 27 OPM %33.7627.23 - PBDT186.53105.74 76 PBT142.4671.65 99 NP100.3853.85 86 Powered by Capital Market - Live

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live

Sai Life Sciences has allotted 8,89,133 equity shares under ESOP on 19 December 2025. Powered by Capital Market - Live

Net profit of Sai Life Sciences rose 101.98% to Rs 83.84 crore in the quarter ended September 2025 as against Rs 41.51 crore during the previous quarter ended September 2024. Sales rose 35.88% to Rs 537.47 crore in the quarter ended September 2025 as against Rs 395.56 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales537.47395.56 36 OPM %27.1325.84 - PBDT151.8091.24 66 PBT112.0555.32 103 NP83.8441.51 102 Powered by Capital Market - Live

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing. Through this partnership, customers will have access to integrated drug substance and drug product development, helping them move efficiently from preclinical studies to first-in-human (FIH) clinical trials and beyond. Powered by Capital Market - Live

Sai Life Sciences has allotted 1,50,500 equity shares under ESOP on 03 September 2025. Powered by Capital Market - Live

 Sai Life Sciences announced the completion of Phase II of its new Production Block (PB-11) at the company's flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL, making it the single largest reactor volume block at the Bidar site. This expansion has taken the company's total installed reactor capacity at the Bidar facility to ~700 KL.Powered by Capital Market - Live